RLAY Stock Analysis: Relay Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.725m USD | 12M Return: 180.5% | US75943R1023 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 45.5M
Warnings
Tailwinds
Seasonality 6.3 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Relay Therapeutics, Inc. (NASDAQ: RLAY) is a clinical-stage precision medicines company headquartered in Cambridge, Massachusetts, focused on small molecule therapeutic discovery in targeted oncology and genetic diseases. The company was incorporated in 2015 (originally as Allostery, Inc.) and went public in July 2020, operating within the biotechnology sub-industry of the health care sector.
Its lead product candidates include RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor in clinical development for breast cancer, solid tumors, and vascular malformations, and an aGal chaperone for Fabry disease. The pipeline also includes RLY-8161, targeting the RAS family of oncogene drivers, and lirafugratinib (RLY-4008), a receptor tyrosine kinase inhibitor for cancer treatment.
Relay Therapeutics has established collaboration and license agreements with D. E. Shaw Research for computational protein motion analysis, Elevar Therapeutics for the development and commercialization of RLY-4008, and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib. As a clinical-stage biotechnology company, it generates limited product revenue and relies heavily on partnerships and capital markets to fund its drug development activities.
- RLY-2608 breast cancer pivotal data readout approaches
- Pfizer partnership milestone payments offset cash burn
- Competition in PI3Kα space intensifies from Novartis
| Net Income: -293.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.24 > 0.02 and ΔFCF/TA 13.41 > 1.0 |
| NWC/Revenue: 5.25k% < 20% (prev 7.08k%; Δ -1.83k% < -1%) |
| CFO/TA -0.24 > 3% & CFO -214.0m > Net Income -293.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (219.2m) vs 12m ago 27.13% < -2% |
| Gross Margin: 76.83% > 18% (prev -3.68k%; Δ 3.75k% > 0.5%) |
| Asset Turnover: 1.95% > 50% (prev 1.25%; Δ 0.71% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 864.9m - Total Current Liabilities 59.2m) / Total Assets 901.7m |
| B: -2.50 (Retained Earnings -2.25b / Total Assets 901.7m) |
| C: -0.41 (EBIT TTM -320.3m / Avg Total Assets 785.8m) |
| D: 9.90 (Book Value of Equity 819.0m / Total Liabilities 82.7m) |
| Altman-Z'' = 5.37 = AAA |
As of November 15, 2026, the stock is trading at USD 18.09 with a total of 1,478,164 shares traded. Over the past week, the price has changed by -2.74%, over one month by +4.21%, over three months by -9.23% and over the past year by +180.47%.
Current recommended Stop Loss: 16.60 (which is 8.2% or 1.3 ATR below the current price).
Relay Therapeutics has received a consensus analysts rating of 4.77. Therefore, it is recommended to buy RLAY.
- StrongBuy: 10
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.6 | 52.5% |
P/S = 359.9428
P/B = 4.2941
Revenue TTM = 15.4m USD
EBIT TTM = -320.3m USD
EBITDA TTM = -316.7m USD
Long Term Debt = 23.5m USD (estimated: total debt 27.0m - short term 3.49m)
Short Term Debt = 3.49m USD (from shortTermDebt, last quarter)
Debt = 57.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 30.7m
Net Debt = -66.5m USD (calculated: Debt 57.7m - CCE 124.2m)
Enterprise Value = 3.66b USD (3.73b + Debt 57.7m - CCE 124.2m)
Interest Coverage Ratio = unknown (Ebit TTM -320.3m / Interest Expense TTM 0.0)
EV/FCF = -17.10x (Enterprise Value 3.66b / FCF TTM -214.0m)
FCF Yield = -5.85% (FCF TTM -214.0m / Enterprise Value 3.66b)
FCF Margin = -1.39k% (FCF TTM -214.0m / Revenue TTM 15.4m)
Net Margin = -1.91k% (Net Income TTM -293.6m / Revenue TTM 15.4m)
Gross Margin = 76.83% ((Revenue TTM 15.4m - Cost of Revenue TTM 3.56m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 4.06 (Enterprise Value 3.66b / Total Assets 901.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 57.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -253.0m (EBIT -320.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.62 (Total Current Assets 864.9m / Total Current Liabilities 59.2m)
Debt / Equity = 0.07 (Debt 57.7m / totalStockholderEquity, last quarter 819.0m)
Debt / EBITDA = 0.21 (negative EBITDA) (Net Debt -66.5m / EBITDA -316.7m)
Debt / FCF = 0.31 (negative FCF - burning cash) (Net Debt -66.5m / FCF TTM -214.0m)
Total Stockholder Equity = 729.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.37% (Net Income -293.6m / Total Assets 901.7m)
RoE = -40.25% (Net Income TTM -293.6m / Total Stockholder Equity 729.6m)
RoCE = -42.53% (EBIT -320.3m / Capital Employed (Equity 729.6m + L.T.Debt 23.5m))
RoIC = -29.94% (negative operating profit) (NOPAT -253.0m / Invested Capital 845.3m)
WACC = 10.96% (E(3.73b)/V(3.78b) * Re(11.13%) + D(57.7m)/V(3.78b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.90 | Cagr: 24.93%
[DCF] Fair Price = unknown (Cash Flow -214.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.46 | # QB: 0
Revenue Correlation: -68.70 | Revenue CAGR: -35.84% | SUE: N/A | # QB: 0
EPS current Quarter (2027-03-31): EPS=-0.39 | Chg30d=+0.68% | Revisions=+25% | Analysts=5
EPS current Year (2026-12-31): EPS=-1.61 | Chg30d=+0.14% | Revisions=-58% | GrowthEPS=-0.2% | GrowthRev=-27.2%
EPS next Year (2027-12-31): EPS=-1.63 | Chg30d=+0.29% | Revisions=-44% | GrowthEPS=-1.1% | GrowthRev=+60.2%
[Analyst] Revisions Ratio: -53% (up=3, down=13)